Live Breaking News & Updates on Final Safety

Stay updated with breaking news from Final safety. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Bristol Myers Squibb's First Disclosures and New Data at ASH 2023 Highlight Company's Leadership and Progress in Cell Therapy, Targeted Protein Degradation and Novel Approaches in Hematology -November 02, 2023 at 11:35 am EDT

First presentation of results from primary analysis of Phase 2 TRANSCEND FL study evaluating second-line treatment with Breyanzi® in relapsed or refractory follicular lymphoma demonstrate its. ....

United States , San Diego , Sikander Ailawadhi , Francesco Passamonti , Lisocabtagene Maraleucel , Guillaume Cartron , Ravi Vij , Maroof Hasan , Mark Kaplan , Rachid Baz , Hemophagocytic Lymphohistiocytosis , Danny Jeyaraju , Sheida Hayati , Susan Bal , Samit Hirawat , Franck Morschhauser , Bristol Myers Squibb , Lauren Peres , Sujit Sheth , Marc Hoffmann , Tracy Chow , Hansc Lee , Michael Wang , Esther Oliva , Leslie Andritsos , Michele Delforge ,

Equillium Announces Oral Presentation at the Tandem Meetings of ASTCT and CIBMTR

Itolizumab was associated with high clinical response rates at Day 15 and 29Responders were able to taper steroids by 70% at Day 29 and 99% at Day 169Itolizumab being evaluated in pivotal Phase 3 EQUATOR study in first-line acute graft-versus-host diseaseLA JOLLA, Calif. (BUSINESS WIRE) $EQ #GVHD Equillium, Inc. ....

United States , John Koreth , Michael Moore , Eq Gvhd Equillium Inc , Harvard Medical School , International Blood Marrow Transplant Research , Exchange Commission , Ono Pharmaceutical Co Ltd , Equillium Inc , Head Of Corporate Communications , Dana Farber Cancer Institute , Tandem Meetings , American Society , Cellular Therapy , International Blood , Marrow Transplant , Final Safety , Efficacy Results , Open Label Study Evaluating Itolizumab , Novel Targeted , Newly Diagnosed Acute Graft Versus Host Disease , Oral Abstract , Graft Versus Host Disease , Biocon Limited , Private Securities Litigation Reform Act , Investor Relations Officer ,

Biogen (BIIB) Presents New Multiple Sclerosis Data

Biogen (BIIB) Presents New Multiple Sclerosis Data
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Nordrhein Westfalen , Maha Radhakrishnan , Charles Weissmann , Walter Gilbert , Heinz Schaller , Allison Parks , Mike Hencke , Diroximel Fumarate , Kenneth Murray , Unilabs Customer Satisfaction Survey , Child Development , Observational Program , Biogen Inc , University Bochum , Exchange Commission , Outcomes On Child Development , European Union , Research In Multiple Sclerosis , European Committee For Treatment , Wall Street , European Committee , Multiple Sclerosis , Chief Medical Officer , Efficacy Results , Highlight Patient Reported Outcomes , Analysis Shows Impact ,

Biogen Inc.: New Data at ECTRIMS 2022 Highlight Biogen's Commitment to Advancing Individualized Disease Management for People Living with MS

Final safety and efficacy results from the Phase 3 EVOLVE-MS-1 trial demonstrate decreases in disease activity and favorable tolerability for VUMERITY (diroximel fumarate) consistent with previous ....

Nordrhein Westfalen , United Kingdom , Maha Radhakrishnan , Charles Weissmann , Walter Gilbert , Heinz Schaller , Allison Parks , Mike Hencke , Diroximel Fumarate , Kenneth Murray , Unilabs Customer Satisfaction Survey , Child Development , Observational Program , University Bochum , Exchange Commission , Outcomes On Child Development , European Union , Research In Multiple Sclerosis , European Committee For Treatment , European Committee , Multiple Sclerosis , Chief Medical Officer , Efficacy Results , Highlight Patient Reported Outcomes , Analysis Shows Impact , Ralf Gold ,

NEURELIS PRESENTS NOVEL, INVESTIGATIONAL ANALYSIS OF valtoco® (DIAZEPAM NASAL SPRAY) civ demonstrating increased time between seizure clusters AT THE 51st Child Neurology Society Annual Meeting

NEURELIS PRESENTS NOVEL, INVESTIGATIONAL ANALYSIS OF valtoco® (DIAZEPAM NASAL SPRAY) civ demonstrating increased time between seizure clusters AT THE 51st Child Neurology Society Annual Meeting
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United States , Adrian Rabinowicz , Erich Sandoval , Brittany Bradrick , Prnewswire Neurelis Inc , Neurelis Inc , Child Neurology Society Annual Meeting , Drug Administration , Clinical Development , Lennox Gastaut Syndrome , Over Time , Pediatric Patients , Long Term Open Label , Repeat Dose Safety Study , Diazepam Nasal Spray , Seizure Clusters , Lennox Gastaut Syndrome Respond Differently , Final Safety , Effectiveness Results From , Neurelis Orphan Drug Exclusivity , Safety Information , Nervous System , Serious Adverse Reactions , Benzyl Alcohol , Prescribing Information , Boxed Warning ,